First-in-class therapy targets "undruggable" protein in hard-to-treat blood cancers

A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood.

Researchers led by Michael Andreeff, M.D., Ph.D., professor, and Yuki Nishida, M.D., Ph.D., assistant professor, both of Leukemia, found that experimental drug GT19630 interrupts a newly discovered cycle between MYC and GSPT1,

from Breaking World Pharma News https://ift.tt/tVBhw25